DRG Epidemiology's coverage of Myasthenia Gravis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of Myasthenia Gravis for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology's Myasthenia Gravis forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Myasthenia Gravis over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, DRG Epidemiology forecasts five Myasthenia Gravis patient populations for Emerging Markets, as follows:

  • Diagnosed prevalent cases
  • Ocular Myasthenia Gravis
  • Generalized Myasthenia Gravis
  • Anti-AchR seropositive Myasthenia Gravis
  • Thymoma Myasthenia Gravis

Note: coverage may vary by country.

Table of contents

  • Myasthenia Gravis - Epidemiology - Emerging Markets
    • Introduction
      • Key Findings
      • Prevalence of Myasthenia Gravis per 100,000 Among People of All Ages in 2020 and 2040
      • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Myasthenia Gravis over the Next Twenty Years
    • Epidemiology data
    • Methods
      • Diagnosed Prevalent cases
      • Myasthenia Gravis Subtypes
      • Anti-AchR Seropositive Myasthenia Gravis
      • Thymoma Myasthenia Gravis
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Myasthenia Gravis
        • Studies Excluded from the Analysis of Myasthenia Gravis
      • Risk/Protective Factors
        • Risk/Protective Factors for Myasthenia Gravis
      • Bibliography
      • Glossary

Author(s): Nishant Kumar, M.P.H.

Nishant Kumar, M.P.H., is an associate director on the Epidemiology team at DRG, part of Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Prior to joining DRG, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.